Entellus Medical (ENTL) Downgraded by BidaskClub
BidaskClub cut shares of Entellus Medical (NASDAQ:ENTL) from a sell rating to a strong sell rating in a report released on Saturday morning.
ENTL has been the topic of a number of other research reports. Zacks Investment Research downgraded shares of Entellus Medical from a buy rating to a hold rating in a research report on Tuesday, October 31st. TheStreet upgraded shares of Entellus Medical from a d rating to a c- rating in a research note on Thursday, December 14th. William Blair cut shares of Entellus Medical from an outperform rating to a market perform rating in a research note on Friday, December 8th. Finally, ValuEngine upgraded shares of Entellus Medical from a sell rating to a hold rating in a research note on Thursday, December 7th. Three analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $19.25.
Entellus Medical (ENTL) opened at $24.02 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.92 and a quick ratio of 1.71. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $25.58. The stock has a market cap of $619.02, a P/E ratio of -18.62 and a beta of -0.02.
A number of hedge funds have recently added to or reduced their stakes in the stock. Sand Grove Capital Management LLP acquired a new stake in Entellus Medical in the 4th quarter worth approximately $33,627,000. ArrowMark Colorado Holdings LLC lifted its stake in Entellus Medical by 28.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 986,137 shares of the medical technology company’s stock valued at $24,052,000 after acquiring an additional 220,961 shares during the period. BlackRock Inc. lifted its stake in Entellus Medical by 10.6% during the 4th quarter. BlackRock Inc. now owns 676,740 shares of the medical technology company’s stock valued at $16,506,000 after acquiring an additional 64,681 shares during the period. Archon Capital Management LLC lifted its stake in Entellus Medical by 4.1% during the 4th quarter. Archon Capital Management LLC now owns 572,804 shares of the medical technology company’s stock valued at $13,971,000 after acquiring an additional 22,580 shares during the period. Finally, Aisling Capital LLC acquired a new stake in Entellus Medical during the 3rd quarter valued at approximately $9,759,000. Institutional investors own 83.44% of the company’s stock.
WARNING: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/02/21/entellus-medical-entl-downgraded-by-bidaskclub.html.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.